Trial Profile
COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2020
Price :
$35
*
At a glance
- Drugs Nomacopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Acronyms COBALT
- Sponsors Akari Therapeutics
- 11 Dec 2020 According to a Akari Therapeutics media release, full clinical details on all 19 PNH patients treated with nomacopan will be provided in a manuscript that is currently in preparation.
- 11 Dec 2020 Results (n=19) derived from COBALT, CAPSTONE and long-term safety study CONSERVE presented in an Akari Therapeutics Media Release.
- 10 Jan 2020 Results presented in an Akari Therapeutics media release.